Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Burkitt Lymphoma 5Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia 3Vomiting 2Nausea 2Lymphoma 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Prostatic Neoplasms 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hypersensitivity 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Blast Crisis 1

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Plasmacytoma × dexamethasone acetate × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡